456 related articles for article (PubMed ID: 25488983)
21. PI3K pathway defects leading to immunodeficiency and immune dysregulation.
Nunes-Santos CJ; Uzel G; Rosenzweig SD
J Allergy Clin Immunol; 2019 May; 143(5):1676-1687. PubMed ID: 31060715
[TBL] [Abstract][Full Text] [Related]
22. Early diagnosis of PI3Kδ syndrome in a 2 years old girl with recurrent otitis and enlarged spleen.
Saettini F; Pelagatti MA; Sala D; Moratto D; Giliani S; Badolato R; Biondi A
Immunol Lett; 2017 Oct; 190():279-281. PubMed ID: 28842185
[TBL] [Abstract][Full Text] [Related]
23. Identification of variations in the human phosphoinositide 3-kinase p110delta gene in children with primary B-cell immunodeficiency of unknown aetiology.
Jou ST; Chien YH; Yang YH; Wang TC; Shyur SD; Chou CC; Chang ML; Lin DT; Lin KH; Chiang BL
Int J Immunogenet; 2006 Oct; 33(5):361-9. PubMed ID: 16984281
[TBL] [Abstract][Full Text] [Related]
24. Successful haploidentical hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase δ syndrome: Case report and literature review.
Yang X; Xi R; Bai J; Pan Y
Medicine (Baltimore); 2023 Feb; 102(5):e32816. PubMed ID: 36749229
[TBL] [Abstract][Full Text] [Related]
25. Establishment of a non-integrated iPSC (SDQLCHi068-A) line derived from a patient with autosomal dominant immunodeficiency-14A carrying a heterozygous mutation (c.3061G>A) in PIK3CD gene.
Xin H; Lv Y; Wei X; Song W; Li Z; Liu Y; Gai Z
Stem Cell Res; 2024 Jun; 77():103385. PubMed ID: 38507881
[TBL] [Abstract][Full Text] [Related]
26. Activated PI3Kδ syndrome type 2: Two patients, a novel mutation, and review of the literature.
Olbrich P; Lorenz M; Cura Daball P; Lucena JM; Rensing-Ehl A; Sanchez B; Führer M; Camacho-Lovillo M; Melon M; Schwarz K; Neth O; Speckmann C
Pediatr Allergy Immunol; 2016 Sep; 27(6):640-4. PubMed ID: 27116393
[TBL] [Abstract][Full Text] [Related]
27. p37δ is a new isoform of PI3K p110δ that increases cell proliferation and is overexpressed in tumors.
Fransson S; Uv A; Eriksson H; Andersson MK; Wettergren Y; Bergo M; Ejeskär K
Oncogene; 2012 Jul; 31(27):3277-86. PubMed ID: 22020336
[TBL] [Abstract][Full Text] [Related]
28. Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase δ Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies.
Karanovic D; Michelow IC; Hayward AR; DeRavin SS; Delmonte OM; Grigg ME; Dobbs AK; Niemela JE; Stoddard J; Alhinai Z; Rybak N; Hernandez N; Pittaluga S; Rosenzweig SD; Uzel G; Notarangelo LD
Front Immunol; 2019; 10():77. PubMed ID: 30891027
[TBL] [Abstract][Full Text] [Related]
29. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
[TBL] [Abstract][Full Text] [Related]
30. A mutation in caspase-9 decreases the expression of BAFFR and ICOS in patients with immunodeficiency and lymphoproliferation.
Clemente N; Boggio E; Gigliotti CL; Orilieri E; Cappellano G; Toth E; Valletti PA; Santoro C; Quinti I; Pignata C; Notarangelo LD; Dianzani C; Dianzani I; Ramenghi U; Dianzani U; Chiocchetti A
Genes Immun; 2015 Mar; 16(2):151-61. PubMed ID: 25569260
[TBL] [Abstract][Full Text] [Related]
31. Identification of a novel de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase δ syndrome.
Luo Y; Xia Y; Wang W; Li Z; Jin Y; Gong Y; He T; Li Q; Li C; Yang J
Clin Immunol; 2018 Dec; 197():60-67. PubMed ID: 30138677
[TBL] [Abstract][Full Text] [Related]
32. Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement.
Brachmann SM; Yballe CM; Innocenti M; Deane JA; Fruman DA; Thomas SM; Cantley LC
Mol Cell Biol; 2005 Apr; 25(7):2593-606. PubMed ID: 15767666
[TBL] [Abstract][Full Text] [Related]
33. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage.
Angulo I; Vadas O; Garçon F; Banham-Hall E; Plagnol V; Leahy TR; Baxendale H; Coulter T; Curtis J; Wu C; Blake-Palmer K; Perisic O; Smyth D; Maes M; Fiddler C; Juss J; Cilliers D; Markelj G; Chandra A; Farmer G; Kielkowska A; Clark J; Kracker S; Debré M; Picard C; Pellier I; Jabado N; Morris JA; Barcenas-Morales G; Fischer A; Stephens L; Hawkins P; Barrett JC; Abinun M; Clatworthy M; Durandy A; Doffinger R; Chilvers ER; Cant AJ; Kumararatne D; Okkenhaug K; Williams RL; Condliffe A; Nejentsev S
Science; 2013 Nov; 342(6160):866-71. PubMed ID: 24136356
[TBL] [Abstract][Full Text] [Related]
34. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
Hon WC; Berndt A; Williams RL
Oncogene; 2012 Aug; 31(32):3655-66. PubMed ID: 22120714
[TBL] [Abstract][Full Text] [Related]
35. Increased activation of PI3 kinase-δ predisposes to B-cell lymphoma.
Durandy A; Kracker S
Blood; 2020 Feb; 135(9):638-643. PubMed ID: 31942637
[TBL] [Abstract][Full Text] [Related]
36. Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO).
Jücker M; Südel K; Horn S; Sickel M; Wegner W; Fiedler W; Feldman RA
Leukemia; 2002 May; 16(5):894-901. PubMed ID: 11986952
[TBL] [Abstract][Full Text] [Related]
37. Expression of the splice variants of the p85alpha regulatory subunit of phosphoinositide 3-kinase in muscle and adipose tissue of healthy subjects and type 2 diabetic patients.
Lefai E; Roques M; Vega N; Laville M; Vidal H
Biochem J; 2001 Nov; 360(Pt 1):117-26. PubMed ID: 11695998
[TBL] [Abstract][Full Text] [Related]
38. Activated PI3Kinase Delta Syndrome-A Multifaceted Disease.
Thouenon R; Moreno-Corona N; Poggi L; Durandy A; Kracker S
Front Pediatr; 2021; 9():652405. PubMed ID: 34249806
[TBL] [Abstract][Full Text] [Related]
39. Agammaglobulinemia and absent B lineage cells in a patient lacking the p85α subunit of PI3K.
Conley ME; Dobbs AK; Quintana AM; Bosompem A; Wang YD; Coustan-Smith E; Smith AM; Perez EE; Murray PJ
J Exp Med; 2012 Mar; 209(3):463-70. PubMed ID: 22351933
[TBL] [Abstract][Full Text] [Related]
40. PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy.
Thauvin-Robinet C; Auclair M; Duplomb L; Caron-Debarle M; Avila M; St-Onge J; Le Merrer M; Le Luyer B; Héron D; Mathieu-Dramard M; Bitoun P; Petit JM; Odent S; Amiel J; Picot D; Carmignac V; Thevenon J; Callier P; Laville M; Reznik Y; Fagour C; Nunes ML; Capeau J; Lascols O; Huet F; Faivre L; Vigouroux C; Rivière JB
Am J Hum Genet; 2013 Jul; 93(1):141-9. PubMed ID: 23810378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
